Type to search

GENFIT Acquires Swiss Biotech Versantis for Over CHF105 Million | Pharmtech Focus
Genoscience Pharma Licences GNS561, its PPT-1 Inhibitor, to GENFIT in Cholangiocarcinoma Indication in US/Canada and Europe | Pharmtech Focus